Proton-Pump Inhibitor use in combination with a CDK4/6 inhibitor: Is formulation the issue?

Oncologist · Published 2026-07-27 · DOI 10.1093/oncolo/oyag293

Free full text

Authors (1)

Calum Polwart

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Polwart, C. (2026). Proton-Pump Inhibitor use in combination with a CDK4/6 inhibitor: Is formulation the issue?. Oncologist. https://doi.org/10.1093/oncolo/oyag293

Related articles

• Patient-driven second opinions in oncology: a review · Oncologist · 2026 · Same journal
• Durable response to sotorasib in KRAS G12C -mutant intrahepatic cholangiocarcinoma: a case report · Oncologist · 2026 · Same journal
• Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy · Oncologist · 2026 · Same journal
• Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial · Oncologist · 2026 · Same journal
• Renal Dysfunction in Patients with CML on Long-Term First-Line TKI Therapy: A Single-Center Analysis · Oncologist · 2026 · Same journal
• SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1 m advanced breast cancer during first-line endocrine-basedtherapy · Oncologist · 2026 · Same journal
• The Role of Adjuvant Chemotherapy in Small Bowel Adenocarcinomas · Oncologist · 2026 · Same journal
• Oncofertility in Gastrointestinal (GI) Oncology – A Pan-European study of the patient perspective · Oncologist · 2026 · Same journal
• Targeted Therapies in the Management of Advanced Medullary Thyroid Cancer · Oncologist · 2026 · Same journal
• Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA -altered metastatic or recurrent gastric cancer · Oncologist · 2026 · Same journal